These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37981494)

  • 1. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
    Eur Urol Oncol; 2024 Apr; 7(2):302-303. PubMed ID: 38000932
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

  • 4. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features.
    Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
    Eur Urol Oncol; 2024 Apr; 7(2):266-274. PubMed ID: 37442673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Pranav Sharma, Asad Sawar and Philippe Spiess' letter to the editor re: re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
    Rogers CG; Barod R; Schwartz S; Menon M
    Eur Urol; 2015 Oct; 68(4):e81. PubMed ID: 26004799
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
    Ishiyama Y; Urabe F
    Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
    Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
    Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Ithaar H. Derweesh, Rana R. McKay, Aditya Bagrodia. Primary Cytoreductive Nephrectomy: Standing the Test of Time? Eur Urol. 2023;83:152-3.
    Mejean A
    Eur Urol; 2023 May; 83(5):e135. PubMed ID: 36781338
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy.
    Esdaille AR; Abel EJ
    Cancer; 2021 Nov; 127(21):3920-3923. PubMed ID: 34286855
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
    Yip W; Ghoreifi A; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):637. PubMed ID: 37316397
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?
    Patel HD; Clark JI; Flanigan RC
    J Urol; 2021 Jul; 206(1):4-6. PubMed ID: 33560871
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
    Massari F; Di Nunno V; Santoni M
    Eur Urol Oncol; 2019 May; 2(3):340-341. PubMed ID: 31200852
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed.
    Kim HL
    Curr Opin Urol; 2020 Sep; 30(5):743-745. PubMed ID: 32732627
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
    Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
    Meza L; Chehrazi-Raffle A; Pal SK
    Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.
    Capitanio U; Larcher A; Montorsi F
    BJU Int; 2019 Jul; 124(1):6-7. PubMed ID: 30656818
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytoreductive nephrectomy: future directions.
    Margulis V; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):540-541. PubMed ID: 31305272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.